Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eplerenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 known ✓ | P08235 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eplerenone SCHEMBL14567750 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL8445849 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14567731 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14284960 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL16144481 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL1818157 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL13061287 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14308852 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL13007056 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL19891818 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14987 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122060012-A | Preparation method of eplerenone and intermediate thereof | 江西百思康瑞药业有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724042-A1 | METHOD FOR IMPROVING THE INGESTION OF A LIQUID OR VISCOUS SUBSTANCE | Ceva Santé Animale (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12590331-B2 | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4684832-A2 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | Vifor (International) Ltd. (CH) | 2026-01-28 | — | — | EP | claimed |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-6245755-B1 | ADMINISTERING EPOXYMEXRENONE WITH INCREASING SODIUM EXCRETION | CURATORS OF THE UNVERSITY OF MISSOURI | 2001-06-12 | — | — | US | claimed |
| WO-2001034132-A2 | USE OF AN ALDOSTERONE ANTAGONIST FOR TREATING RESTENOSIS | PHARMACIA CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2000051642-A1 | COMBINATION THERAPY OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST FOR TREATMENT OF CARDIOVASCULAR DISEASE | G.D. SEARLE LLC (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000038725-A1 | COMBINATIONS FOR CARDIOVASCULAR INDICATIONS | G.D. SEARLE LLC (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000033847-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000027380-A2 | COMBINATION THERAPY OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ALDOSTERONE ANTAGONIST FOR REDUCING MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASE | G.D. SEARLE & CO. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000021509-A2 | METHODS OF TREATMENT | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2000-04-20 | — | — | WO | claimed |
| US-6008210-A | ADMINISTERING EPOXYMEXRENONE | CURATORS OF THE UNIVERSITY OF MISSOURI, THE | 1999-12-28 | — | — | US | claimed |
| EP-0730458-A1 | USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MYOCARDIAL FIBROSIS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1996-09-11 | — | — | EP | claimed |
| WO-1995015166-A1 | USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MYOCARDIAL FIBROSIS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1995-06-08 | — | — | WO | claimed |